A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Public ClinicalTrials.gov record NCT05578092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Study identification
- NCT ID
- NCT05578092
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 64 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2, 2022 (Actual)
- Primary completion
- Feb 3, 2026 (Actual)
- Completion
- Feb 3, 2026 (Actual)
- Last update posted
- Feb 19, 2026
2022 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 001-108 | New Haven | Connecticut | 06520 | — |
| Local Institution - 001-119 | Newark | Delaware | 19713-2055 | — |
| Local Institution - 001-111 | Orlando | Florida | 32827-7400 | — |
| Local Institution - 001-103 | Baltimore | Maryland | 21287 | — |
| Local Institution - 001-110 | Rochester | Minnesota | 55905-0001 | — |
| Local Institution - 001-115 | Hackensack | New Jersey | 07601-2191 | — |
| Local Institution - 001-106 | Cincinnati | Ohio | 45219-2364 | — |
| Local Institution - 001-109 | Portland | Oregon | 97239-3011 | — |
| Local Institution - 001-116 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 001-101 | Nashville | Tennessee | 37203 | — |
| Local Institution - 001-102 | Nashville | Tennessee | 37203 | — |
| Local Institution - 001-112 | Dallas | Texas | 75246-2003 | — |
| Local Institution - 001-122 | Fort Worth | Texas | 76104-2154 | — |
| Local Institution - 001-107 | Houston | Texas | 77030 | — |
| Local Institution - 001-123 | Tyler | Texas | 75708-3154 | — |
| Local Institution - 001-104 | Fairfax | Virginia | 22031 | — |
| Local Institution - 001-105 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05578092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05578092 live on ClinicalTrials.gov.